ONC offers more details about enhanced certification proposed rule

During the most recent Health IT Joint Committee meeting, the Office of the National Coordinator for Health IT (ONC) took the opportunity to clear up confusion about the proposed rule regarding enhanced health IT oversight and accountability.

“The goal is enhanced oversight,” said Elise Sweeney Anthony, acting director of ONC’s Office of Policy Planning.

The rule would not create new certification requirements for health IT developers or new certification requirements for providers participating in Department of Health and Human Services programs. It also would not establish a means for ONC to directly test and certify health IT and would not establish regular or routine auditing of certified health IT by ONC. ONC’s authorized certification bodies (ACBs) will continue to test and certify health IT.

The proposed rule would:

  • Enable ONC to directly review already certified health IT products.
  • Enable increased ONC oversight of health IT testing bodies
  • Enable increased transparency and accountability by making identifiable surveillance results of certified health IT publicly available.

Anthony offered examples of what might warrant ONC direct review. If a developer has products certified by two different certification bodies and ONC receives a complaint, “it might make sense for ONC to engage in a review rather than have multiple ACBs review.”

She also noted that ONC could step in if there is a risk to public health or safety or something could compromise the security or protection of patients’ health information.

Suspension can occur anywhere in the process “because we want to be able to step in quickly.” There are opportunities for appeal and correction action is key. “We really hope and intend to work with developers on how to address the problem.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.